menu
    • menu
    [{"orgOrder":0,"company":"Dren Bio","sponsor":"Taiho Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"DR-01","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Dren Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Dren Bio \/ Taiho Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dren Bio \/ Taiho Ventures"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bispecific Antibody","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Dren Bio","amount2":1.03,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"","sponsorNew":"Dren Bio \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"Dren Bio \/ Pfizer Inc"},{"orgOrder":0,"company":"Dren Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Acquisition","leadProduct":"DR-0201","moa":"CD20","graph1":"Immunology","graph2":"Phase I","graph3":"Dren Bio","amount2":1.8999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":1.8999999999999999,"dosageForm":"Intravenous","sponsorNew":"Dren Bio \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Dren Bio \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Dren Bio

    Menu

    Dren Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DR-0201

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi to Acquire Dren Bio's Immunology Unit

                            Details : Sanofi acquires DR-0201 from Dren. It is CD20-directed bispecific antibody that targets & engages specific tissue-resident & trafficking myeloid cells to induce deep B-cell depletion.

                            Product Name : DR-0201

                            Product Type : Antibody

                            Upfront Cash : $600.0 million

                            March 20, 2025

                            Lead Product(s) : DR-0201

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Sanofi

                            Deal Size : $1,900.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $1,025.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple T...

                            Details : The strategic collaboration will focus on the discovery and development of therapeutic bispecific antibodies for selected oncology targets using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : $25.0 million

                            January 11, 2022

                            Lead Product(s) : Bispecific Antibody

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Pfizer Inc

                            Deal Size : $1,025.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed

                            Dren Bio

                            U.S.A arrow
                            Immuno-Oncology 360
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DR-01

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Taiho Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Dren Bio Announces a $60M Series A Financing

                            Details : Dren will utilize the proceeds to advance its two lead programs through early clinical development. Dren’s first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders.

                            Product Name : DR-01

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 16, 2020

                            Lead Product(s) : DR-01

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Taiho Ventures

                            Deal Size : $60.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth